The AXL-PYK2-PKCα axis as a nexus of stemness circuits in TNBC
Lohit Khera, Yaron Vinik, Flavio Maina, Sima Lev

To cite this version:
Lohit Khera, Yaron Vinik, Flavio Maina, Sima Lev. The AXL-PYK2-PKCα axis as a nexus of stemness circuits in TNBC. Life Science Alliance, Life Science Alliance LLC, 2021, 4 (6), pp.e202000985. 10.26508/lsa.202000985. hal-03429753

HAL Id: hal-03429753
https://hal.archives-ouvertes.fr/hal-03429753
Submitted on 20 Nov 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution 4.0 International License
The AXL-PYK2-PKCa axis as a nexus of stemness circuits in TNBC

Lohit Khera¹, Yaron Vinik¹, Flavio Maina², Sima Lev¹

Cancer stem cells (CSCs) are implicated in tumor initiation, metastasis and drug resistance, and considered as attractive targets for cancer therapy. Here we identified a clinically relevant signaling nexus mediated by AXL receptor, PYK2 and PKCa and show its impact on stemness in TNBC. AXL, PYK2, and PKCa expression correlates with stemness signature in basal-like breast cancer patients, and their depletion in multiple mesenchymal TNBC cell lines markedly reduced the number of mammosphere-forming cells and cells harboring CSCs characteristic markers. Knockdown of PYK2 reduced the levels of AXL, PKCa, FRA1, and PYK2 proteins, and similar trend was obtained upon PKCa depletion. PYK2 depletion decreased AXL transcription through feedback loops mediated by FRA1 and TAZ, whereas PKCa inhibition induced redistribution of AXL to endosomal/lysosomal compartment and enhanced its degradation. PYK2 and PKCa cooperate at a convergence point of multiple stemness-inducing pathways to regulate AXL levels and concomitantly the levels/activation of STAT3, TAZ, FRA1, and SMAD3 as well as the pluripotent transcription factors Nanog and Oct4. Induction of stemness in TNBC sensitized cells to PYK2 and PKCa depletion. PYK2 and PKCa inhibition suggesting that targeting the AXL-PYK2-PKCa circuit could be an efficient strategy to eliminate CSCs in TNBC.

Introduction

Cancer stem cells (CSCs) represent a small fraction of cancer cells, characterized by specific cellular markers, self-renewal and tumor-initiating capacities (1,2). This subpopulation of cells, also known as tumor-initiating cells (TICs), are commonly associated with drug-resistance and metastatic potential, and are considered as promising targets for therapeutic intervention.

Breast cancer (BC)-initiating cells typically express high levels of CD44, a surface receptor for the extracellular matrix protein Hyaluronan, low levels of CD24, and exhibit high aldehyde dehydrogenase (ALDH) activity (3). Other cell surface proteins, including CD326 (EpCAM), epithelial specific antigen, CD133, CD166, CD47, CD201, and ABCG2 have been reported as CSC markers for different BC subtypes and drug-resistant tumors (4, 5). CD44⁺/CD24⁻ ratio is particularly enriched in CSCs of triple negative breast cancer (TNBC) (6), a highly aggressive BC subtype defined by the absence of estrogen and progesterone hormone receptors, and of HER2 amplification (7).

Multiple studies have shown that CSCs have the capacity to regenerate bulk tumors that are mostly composed of non-cancer stem cells (NCSCs) (8), whereas NCSCs can dedifferentiate and acquire a CSC phenotype upon epithelial mesenchymal transition (EMT) (9). EMT is a multistep process involved in cancer metastasis, mediated by activation of Slug/Snail, Twist and/or Zeb transcription factors (TFs), and characterized by a specific gene signature. Importantly, EMT and BC initiating cells display very similar gene signatures and phenotypic properties (9, 10).

Previously we showed that the non-receptor tyrosine kinase PYK2 positively regulates EMT in TNBC (11). Similarly, the tyrosine kinase receptor AXL of the TAM (Tyro-Axl-Mer) family was reported to be essential for EMT in BC and to regulate CSC self-renewal and chemoresistance (12, 13, 14). AXL up-regulation in several human cancers including TNBC (15) is frequently associated with resistance to different chemotherapeutic agents and targeted therapies, including MEK (16), PI3K/AKT, BET, and EGFR (17). These observations underscore the potential clinical benefit of AXL inhibition/down-regulation in drug-resistant tumors, which commonly display EMT properties and are enriched in CSCs (18).

Numerous studies have highlighted the role of different signaling pathways and signaling intermediates in regulating BC stem cells (BCSCs) self-renewal and maintenance of stemness properties, including the TGFβ, IL6/IL8, Hedgehog, Notch, Wnt, AXL, and the Hippo pathways (6). TGFβ, a potent EMT inducer in mammary cells, enhances stemness of chemotherapy-resistant TNBC cells (19). Activation of STAT3 signaling by different growth factors and cytokines including IL6, has been implicated in EMT, self-renewal of BCSCs as well as acquisition of stemness properties of doxorubicin resistant TNBC cells (20, 21), whereas TAZ was reported to be essential for metastatic activity and chemoresistance of BCSCs (22). Different signaling components, including the gap junction protein...
The substantial effects of PYK2 KD on AXL and PKCα proteins by WB. As shown in Fig 3A, FRA1 KD reduced the level of FRA1 protein and mRNA levels (Fig 3E). Collectively, our data show that AXL is regulated by the transcriptional co-activator TAZ (33), and we previously shown that AXL is a universal target of FRA1 (30, 31), and previous studies suggest that PKCα (27) and AXL are upstream activators of FRA1 (32). FRA1 levels were examined in PYK2-, PKCα-, or AXL-depleted M/MSL TNBC cell lines (the four representative M/MSL cell lines). As shown in Fig 2A, depletion of PYK2 substantially reduced the level of FRA1 and its phosphorylation (pS265) (Fig S3A) in all four cell lines. PKCα-deletion reduced the level of FRA1 protein in all the lines except SUM159 (Fig 2A), whereas AXL-depletion had no significant effects on either total PYK2, PKCα, or FRA1 (Fig S3B and C). Nevertheless, R428, an AXL kinase inhibitor, reduced FRA1 phosphorylation in the four cell lines (Fig S3D) as expected. Intriguingly, PKCα knockdown also reduced the protein levels of PYK2 and AXL to different extents (Figs 2A and S3E) and similar effects were obtained by the PKCα inhibitor RO 31-8220 (Fig S3F). The mutual effects of PYK2 and PKCα on each other, and on the protein levels of AXL and FRA1, indicate a putative signaling circuit consisting AXL-PYK2-PKCα-FRA1.

To better characterize this circuit, we assessed the impact of PYK2 or PKCα depletion on the transcription levels of FRA1 as well as of other components of the circuit by qRT-PCR. As shown, PKCα depletion had no significant effects on FRA1 or AXL transcripts; it slightly reduced the expression level of FRA1 in MDA-MB-231 and of PYK2 in SUM159 cells (Fig 2B and C), whereas KD of PYK2 markedly reduced the level of FRA1 (Fig 2B) concomitant with AXL and PKCα transcripts in the four cell lines (Fig 1E). These results suggest that PYK2 depletion affects AXL level through a feedback loop mediated by FRA1. To explore this possibility, we knocked down FRA1 in the four TNBC cell lines and assessed its influence on AXL, PKCα, and PYK2 proteins by WB. As shown in Fig 3A, FRA1 KD reduced the steady-state levels of AXL and PKCα in all the lines, and qRT-PCR analysis revealed ~30–50% reduction in AXL and PKCα transcripts (Fig 3B). The partial effects of FRA1 KD on AXL transcript imply that an additional TF might be involved. Indeed, it was previously shown that AXL is regulated by the transcriptional co-activator TAZ (33), and we previously showed that PYK2 stabilizes TAZ in multiple TNBC cell lines (34), suggesting that the effects of PYK2 on AXL could be mediated by both FRA1 and TAZ. Consistent with this hypothesis, we found that PYK2 depletion indeed reduced TAZ levels in all four M/MSL lines (Fig 3C), and that TAZ inhibitor verteporfin reduced AXL protein (Fig 3D) and mRNA levels (Fig 3E). Collectively, our data show the interdependency between the proteins of the AXL-PYK2-PKCα-FRA1 circuit as summarized in Fig 3F.

**FRA1 is regulated by PYK2 and PKCα and affects AXL and PKCα levels**

The significant effects of PYK2 KD on AXL and PKCα transcripts led us to examine its influence on the level and activation of FRA1 TF. It was previously shown that AXL is a universal target of FRA1 (30, 31), and previous studies suggest that PKCα (27) and AXL are upstream activators of FRA1 (32). FRA1 levels were examined in PYK2-, PKCα-, or AXL-depleted M/MSL TNBC cell lines (the four representative M/MSL cell lines). As shown in Fig 2A, depletion of PYK2 substantially reduced the level of FRA1 and its phosphorylation (pS265) (Fig S3A) in all four cell lines. PKCα-deletion reduced the level of FRA1 protein in all the lines except SUM159 (Fig 2A), whereas AXL-depletion had no significant effects on either total PYK2, PKCα, or FRA1 (Fig S3B and C). Nevertheless, R428, an AXL kinase inhibitor, reduced FRA1 phosphorylation in the four cell lines (Fig S3D) as expected. Intriguingly, PKCα knockdown also reduced the protein levels of PYK2 and AXL to different extents (Figs 2A and S3E) and similar effects were obtained by the PKCα inhibitor RO 31-8220 (Fig S3F). The mutual effects of PYK2 and PKCα on each other, and on the protein levels of AXL and FRA1, indicate a putative signaling circuit consisting AXL-PYK2-PKCα-FRA1.

**Results**

**Interplay between AXL, PYK2, and PKCα in TNBC**

Previous studies have shown that AXL expression is strongly induced during EMT, drug resistance and metastasis in BC (13, 17). Expression profiling analysis revealed its high enrichment in MSL subtype of TNBC patients (28) (Fig 1A). Further analysis of TNBC patients from The Cancer Genome Atlas (TCGA) dataset showed high correlation between AXL and PTK2B (PYK2 gene) expression ($r = 0.5, P < 0.001$), AXL and PKCα (PKCα gene) expression ($r = 0.37, P < 0.001$), and AXL and the EMT markers, CD44 ($r = 0.24, P = 0.01$) and vimentin ($0.328, P = 0.01$) (Fig 1B). High levels of AXL transcript were also observed in M/MSL TNBC cell lines of the Cancer Cell Line Encyclopedia (CCLE) (Fig S1A and B). Western blot (WB) analysis confirmed high level of AXL protein in M/MSL cell lines (MDA-MB-231, SUM159, Hs578T, and BT549) compared to basal-like (HCC70, MDA-MB-468) TNBC cell lines (Fig 1C). Similarly, PKCα, which was shown to be essential for BCSC formation (27), and the characteristic CSCs marker CD44 (4), were also enriched in M/MSL cell lines (Fig 1C).

We previously showed that PYK2 depletion markedly reduced the level of CD44 in TNBC cells (11), and further analysis of at least four different M/MSL TNBC cell lines showed profound effects of PYK2 knockdown (KD) on the steady-state levels of AXL and PKCα (Figs 1D and S1C). However, depletion of FAK, a closely related kinase of PYK2 (29), had marginal effects on the protein levels of PKCα or AXL, and similar effects were obtained with the FAK specific kinase inhibitor PF228 (Fig S1D). The dual PYK2/FAK kinase inhibitor (PF396) reduced the steady-state level of AXL but had no effect on the steady-state levels of PKCα (Fig S1D), thus highlighting the specific influence of PYK2.

The substantial effects of PYK2 KD on AXL and PKCα levels in multiple M/MSL TNBC lines led us to examine its influence on their transcripts using qRT-PCR. As shown in Fig 1E, PYK2 KD reduced the transcript levels of PKCα and AXL (by ~50–70%) in the four representative M/MSL cell lines; SUM-159, MDA-MB-231, Hs578T, and BT-549 (will be used throughout this study). The proteasomal inhibitor MG132 as well as the lysosomal inhibitors Chloroquine and NH4Cl could not restore the protein levels of AXL or PKCα in PYK2 KD cells (Fig S2). Collectively, these results indicate that PYK2 depletion markedly affects the transcript and protein levels of AXL and PKCα in M/MSL TNBC cell lines.

**AXL-PYK2-PKCα axis in TNBC stemness**

Khera et al. | vol 4 | no 6 | e202000985 | https://doi.org/10.26508/lsa.202000985
Figure 1. AXL expression correlates with PYK2 and PKCα in triple negative breast cancer (TNBC) and is influenced by PYK2 expression.

(A) Expression of AXL in TNBC patients from 19 datasets (taken from reference 28). The expression level was normalized for each dataset. TNBC subtypes: BL1 and BL2, basal-like 1 and 2; IM, immunomodulatory; LAR, luminal androgen-receptor positive; M, mesenchymal; MSL, mesenchymal stem-like; UNS, unspecified. (B) Pearson’s correlation between the expression of AXL and other genes in The Cancer Genome Atlas BL breast cancer patients (n = 142 patients). PRKCA encodes PKCα, PTK2B encodes PYK2, VIM encodes Vimentin. (C) Western blot analysis of AXL, PYK2, PKCα, and CD44 in four M/MSL (MDA-MB-231, SUM159, Hs578T, and BT549) and two BL (HCC70, MDA-MB-468) TNBC cell lines. (D) Western blot analysis of the indicated proteins in control, PYK2 knockdown (KD), or FAK KD TNBC (M/MSL) cell lines. The protein levels were
PKC inhibition modulates AXL trafficking and lysosomal degradation of AXL and PYK2

Whereas PYK2 depletion/inhibition reduced the transcription levels of AXL (Fig 1D and E), PKCα depletion/inhibition mainly affected the levels of AXL and PYK2 proteins (Figs 2A and S3D). To examine whether PKCα inhibition affects AXL degradation, RO-31-8220–treated cells were incubated with either MG132 or chloroquine. As seen, chloroquine treatment partially increased AXL and PYK2 levels in RO-31-8220–treated cells (Fig S4A), suggesting that inhibition of PKCα may facilitate the lysosomal degradation of AXL and PYK2. To further characterize the effect of PKCα on AXL and PYK2 fate, we examined their subcellular localization at different time points after PKCα inhibition. As shown in Fig 4A, short-term treatment for 2 h of SUM159 cells with the RO-31-8220 PKC inhibitor caused a redistribution of AXL and PYK2 from the cell-surface and focal adhesions, respectively, into punctate structures that were distributed throughout the cytosol, and largely colocalized with lysotracker.
Figure 3. FRA1 and TAZ levels are influenced by PYK2 and affect AXL transcription.
(A) Western blot (WB) analysis of the indicated proteins in the control and FRA1 KD triple negative breast cancer (mesenchymal/mesenchymal stem-like [M/MSL]) cell lines. (B) Bar graphs showing RT-qPCR analysis of FRA1, PKCα and AXL transcripts in FRA1 KD compared with control cells. Mean values ± SD of three experiments each for MDA-MB-231 and BT549, and two experiments each for SUM159 and Hs578T are shown. (C) WB analysis of TAZ protein in the indicated control and PYK2 KD cell lines. (D, E) The indicated triple negative breast cancer M/MSL cell lines were treated with 1 μM verteporfin (Vp) for 24 h. Controls were treated with equal volume of DMSO. WB (D) and qRT-PCR analysis (E) of AXL protein and transcript levels, respectively, are shown. Mean values ± SD of three experiments are shown. P-values of FRA1 KD or verteporfin treatment versus control (t test)* < 0.05; ** < 0.01. (F) Heat map of protein levels of the AXL-PYK2-PKCα-FRA1 axis in the four M/MSL cell lines, in PYK2-, PKCα-, or FRA1-KD cells. Mean values of two experiments were used to generate the heat map.
Similar effects were obtained with two additional PKC inhibitors (Gö6983 and GF109203X, Fig S4B). Localization studies using different cellular markers showed that PYK2- and AXL-positive punctate structures failed to colocalize with the early endosomal marker EEA1 (Fig S5A), marginally colocalized with the fast-recycling endosomal marker Rab4 (Fig 4B), but were strongly colocalized with Rab11, with the late endosomal/lysosome markers CD63 and CD9 (Fig 4B–D and Table S1), Lamp1 (Fig S5B) and with lysotracker (Fig 4A and Table S1). Strong
colocalization with lysotracker was obtained with both AXL and pPYK2, concomitant with a significant increase in lysotracker signal intensity (Fig S5B) implying enhanced lysosomal activity (35). Colocalization with Rab11 was not observed with all Rab11-positive structures, but particularly with enlarged structures that likely represent late endosome/lysosome compartment (35), as Rab11 not only regulates recycling endosomes but also their fusion with multivesicular bodies (MVBs) (36), which can subsequently fuse with the lysosome. These results suggest that PKC inhibition impairs the endosomal–lysosomal pathway, and enhances rapid translocation of PYK2 to CD9-positive structures (Fig 4D) and lysosomal compartment (Figs 4A and S5B), where it was colocalized with AXL. These observations highlight a unique mode to control PYK2 and AXL levels and their downstream signals. Notably, PYK2/AXL–positive punctate structures could be captured at a narrow time window (2–4 h) using PKC inhibitors in the different M/MSL cell lines, but not in PKCa-depleted cells.

**The AXL-PYK2-PKCα axis correlates with stemness signatures in TNBC**

Previous studies showed that PKCα and its downstream effector FRA1 play key roles in driving CSCs of basal-like BC (27), implying that the AXL-PYK2-PKCα axis, which markedly affects FRA1 levels/phosphorylation (Figs 2A and S3A and D), also regulates CSCs in TNBC. To assess the clinical relevance of this hypothesis, we first performed gene set enrichment analysis (GSEA) on basal-like BC patients of the TCGA dataset (n = 142), ranking the gene expression based to their correlation to PRKCA (PKCα) expression. This analysis revealed a significant positive enrichment of two stemness-related signatures (LIM_MAMMARY STEM_CELL and BOQUEST STEM_CELL_UP (4, 37, 38) (Fig 5A). Similar results were also obtained for PTK2B (PYK2) (Fig S5B) and AXL (Fig 5C). Leading edge analysis of PTK2B and PKRCA enrichment plots (Fig 5A and B) revealed 16 common genes at the leading-edge sets of both signatures. Among these 16 genes, AXL appeared at the top, as the most correlated gene to PTK2B (PYK2), and the third highest correlated gene to PRKCA (Fig 5D). These results highlight the clinical relevance of the AXL-PYK2-PKCα axis to stemness in basal-like BC patients.

We next examined possible relation between PYK2 and PKCα expression and most prominent CSC-associated pathways, including the WNT, Hedgehog, TGFβ, IL6, and IL8 pathways (39). To this end, we scored each basal-like BC patient in the TCGA dataset for each of the five pathways using single sample gene set enrichment analysis (GSEA) on basal-like BC patients of the TCGA dataset (n = 142), ranking the gene expression based to their correlation to PRKCA (PKCα) expression. This analysis revealed a significant positive enrichment of two stemness-related signatures (LIM_MAMMARY STEM_CELL and BOQUEST STEM_CELL_UP (4, 37, 38) (Fig 5A). Similar results were also obtained for PTK2B (PYK2) (Fig S5B) and AXL (Fig 5C). Leading edge analysis of PTK2B and PKRCA enrichment plots (Fig 5A and B) revealed 16 common genes at the leading-edge sets of both signatures. Among these 16 genes, AXL appeared at the top, as the most correlated gene to PTK2B (PYK2), and the third highest correlated gene to PRKCA (Fig 5D). These results highlight the clinical relevance of the AXL-PYK2-PKCα axis to stemness in basal-like BC patients.

To demonstrate the enrichment of stem cell signature in vitro, we analyzed PYK2 KD and control (PLKO) MDA-MB-231 cells by RNAseq (Fig S6B). We generated a ranked gene list, ordered by their fold change in expression between PYK2 KD and control (PLKO). Using GSEA on this list, we observed a negative enrichment score of the BOQUEST STEM_CELL_UP signature that we have used for the patients above (Fig 5F, left), indicating that this signature is enriched in control (PLKO) and decreased in PYK2 KD cells, consistent with our dataset analysis. To strengthen this observation, in a more TNBC-related signature, we used a dataset of SUM159 cells sorted into stemness enriched population versus non-enriched population (GSE52262, (40)). The top 500 genes most significantly expressed in the stemness enriched population were highly expressed in control versus the PYK2 KD cells (Fig 5F, middle). Furthermore, we observed a significant negative enrichment of targets genes of IL6 signaling via STAT3 (Fig 5F, right). Together, these findings strongly suggest that the AXL-PYK2-PKCα axis is associated with CSCs signature of TNBC patients.

**The AXL-PYK2-PKCα axis regulates stemness in TNBC**

To assess the phenotypic impact of the AXL-PYK2-PKCα axis on stemness, we performed a mammosphere formation assay as described in the Materials and Methods section. Hs578T and SUM159 were used as representative cell lines because of their established capability to generate mammospheres in vitro (41). As shown in Fig 6A, knocking down of PYK2, PKCα, or AXL markedly reduced the number of primary and secondary mammospheres compared with control cells (Figs 6A and S7A), highlighting their impact on maintaining the number of TICs and their self-renewal. We further showed by FACS analysis that PYK2 or PKCα depletion reduced the ratio of CD44 to CD24 levels on SUM159 cells surface (Figs 6B and S7B), and thus stem-cell enriched population (42). Similar trend was observed in PK2-depleted MDA-MB-231 cells using the CD44+/CD201 (PROCR) ratio as a marker for stem-cell enriched population (43). Consistent with these results, we found that depletion of PYK2, PKCα, or AXL in the four M/MSL cell lines reduced the number of colonies in a colony formation assay for CSCs (44) (Fig 5C). Moreover, qRT-PCR analysis of PYK2, PKCα, and AXL transcripts in CD44+/CD24− or CD44+CD24− sorted subpopulations of SUM159 cells, revealed their higher expression levels in the CD44−/CD24− stemness enriched population (Fig 6C); collectively these results highlight the impact of the AXL-PYK2-PKCα axis on stemness in TNBC.

Key pluripotent TFs, including Nanog, Oct4, and Sox2 (NOS) are required for embryonic stem cell (ES) self-renewal (45) and their target genes (NOS targets) are significantly enriched in CSCs of TNBC (46, 47). We, therefore, assessed the influence of PYK2 and PKCα depletion on their steady-state levels by WB. As shown in Fig 6D, knocking down of PYK2 reduced the levels of Oct4, Nanog and concomitantly CD44 in all the four M/MSL TNBC cell lines, without detectable effects on Sox2 (not shown), whereas PKCα knockdown reduced Nanog levels.

Concurrent with these observations, we found that the signatures of Oct4 and Nanog target genes (taken from reference 48) are significantly enriched in basal-like BC patients from the TCGA dataset when the genes were ranked by their correlation to PYK2 expression (Fig 6E). Similar results were observed in the RNAseq analysis performed on MDA-MB-231 PYK2 KD cells (Fig S7D). The expression levels of 166 targets of all three factors (Nanog, Oct4, and Sox2) clustered the PYK2 highly expressed basal-like BC patients separately from the PYK2 low-expressing
Figure 5. Gene set enrichment analysis (GSEA) of The Cancer Genome Atlas basal-like breast cancer (BC) patients in correlation to the AXL-PYK2-PKCα axis expression.

(A, B, C) GSEA analysis of The Cancer Genome Atlas basal-like BC patients (n = 142). (A, B, C) For the analysis, all genes were ranked by their Pearson’s correlation to the gene expression of PRKCA (PKCα) (A), PTK2B (PYK2) (B), and AXL (C). The enrichment of two stemness signatures in these gene lists is shown and quantified as the normalized enrichment score (NES). (A, B, D) Leading edge analysis was performed on the GSEA results from (A) and (B). The leading-edge set is composed of genes from the signature that appear before the enrichment score peak is reached (genes that contribute the most to the enrichment score). (A, B) The Venn diagram (left) shows the intersections of the leading-edge sets in the four GSEA plots from (A) and (B). The 16 genes of the intersection from the four sets are shown in the plot on the right, with their correlations to PYK2 and PKCα gene expression. The genes are ordered by their correlation to PKR2 expression. (C) GSEA normalized enrichment scores (NES) for stemness-related pathways. Enrichment was measured in gene expression data of basal BC patients ranked by correlation to PTK2B (PYK2) or PRKCA (PKCα) expression. Line width represents the NES. (E) RNAseq results of PYK2 KD and control (PLKO) MDA-MB-231 cells were used to generate ranked list of genes based on fold change. Enrichment of the indicated signatures was performed using GSEA.
Figure 6. AXL-PYK2-PKCα axis regulates stemness in triple negative breast cancer.

(A) Mammosphere formation assay was performed using SUM159 and Hs578T cell lines. The plot shows the percent of primary (1G) or secondary (2G) mammosphere formed (compared with control). Means ± SD of three independent repeats are shown. Representative images are shown to the right (Scale bar, 200 μm), and in Fig S7A.

(B) FACS analysis of stemness surface markers. For SUM159, the CD44/CD24 fluorescence ratio is shown (Means ± SD of three independent repeats). For MDA-MB-231 the decrease in CD44+/CD201+ population is shown (Means ± SD of two independent repeats). Gating is shown in Fig S7B. P-value of KD versus control (*t test* < 0.05; ** < 0.01; *** < 0.001).

(C) SUM159 cells were sorted by FACS into stemness enriched (CD44+/CD201−) and non-stemness enriched (CD44+/CD201+) populations. Gating for the sort is shown in the middle. Fold change in gene expression was determined and is shown in the right panel.

(D) Heatmap showing gene expression levels in SUM159, MDA-MB-231, Hs578T, and BT549 cell lines with or without AXL-PYK2-PKCα axis activation. The heatmap was generated using the GSEA of basal patients.

E. GSEA of basal patients

| Signature      | NES  | p-value | FDR  |
|----------------|------|---------|------|
| OCT4 targets   | 1.18 | <0.01   | 0.127|
| NANOG targets  | 1.16 | <0.01   | 0.109|
| SOX2 targets   | 0.79 | n.s.    | 0.984|
patients (Fig 6F), demonstrating the clinical correlation between PYK2 expression and the activity of Nanog and Oct4 in those patients, and further highlighting the clinically relevance of our findings.

**TGFβ enhances stemness in TNBC and vulnerability to PYK2 and PKC inhibition**

Previous studies showed that TGFβ plays central role in EMT and cancer stemness (49) and enhanced stem-like properties of TNBC (19). Consistent with these reports, we found that pre-treatment of SUM159 cells with TGFβ for 72 h significantly increased the number of mammospheres as compared with naive SUM159 cells (Fig 7A), and that knockdown of either PYK2 or PKCa reduced mammosphere numbers in both conditions (Fig 7A), implying that PYK2 and PKCa influence TGFβ-induced stemness signaling. To explore this possibility, we first examined whether PYK2 undergoes phosphorylation (pY402) in response to TGFβ stimulation (Fig 7B), and subsequently assessed the impact of PYK2 or PKCa depletion/inhibition on TGFβ downstream signals by monitoring SMAD3 phosphorylation (Fig 7C and D). As shown, TGFβ-induced strong phosphorylation of its downstream effector SMAD3 as well as of PYK2 30 min after treatment (Fig 7B), and inhibition of either PYK2 or PKCa by PF396 or RO-31-8220, respectively, markedly reduced SMAD3 phosphorylation, whereas their co-inhibition completely abolished phosphorylation of SMAD3 in the four examined TNBC cell lines (Fig 7D). Interestingly, the reduced phosphorylation of SMAD3 was associated with decrease in the steady-state level of SMAD3 protein. Knockdown of either PYK2 or PKCa also reduced pSMAD3 concomitant with total SMAD3 levels (Fig 7C), suggesting that PYK2 and PKCa cooperate downstream to TGFβ-receptor signaling.

In light of these results, we examined whether treatment with TGFβ, which enhances stemness (50), would increase vulnerability to PYK2 and/or PKCa inhibition. As shown, pre-treatment of either SUM159 or MDA-MB-231 with TGFβ, sensitized the cells to the PKC inhibitor RO-31-8220 or the PYK2/FAK dual-inhibitor PF396 (Figs 7E and 6 and S8A and B) but not to the FAK specific inhibitor PF228 (Fig S8B). Importantly co-inhibition of PKCa and PYK2/FAK substantially reduced cell viability in TGFβ-treated cells compared with TGFβ-un-treated cells and displayed synergistic effect (combination index = 0.67 and 0.75 for SUM159 and MDA-MB-231, respectively, at 75% cell death) (Fig 7F), implying that stem cells could be more vulnerable to PKCa and PYK2 co-inhibition.

**Cooperation between PYK2 and PKCa modulates key stemness TFs**

The remarkable effects of PYK2 and PKCa on the stemness properties of TNBC cell lines (Fig 6), and their established role as downstream effectors of multiple signaling pathways (51), suggest that these two kinases function as signaling nodes to converge stemness-related signaling pathways. As AXL activation induces EMT and is implicated in stemness (12), we first examined if AXL activation by its cognate ligand GAS6 induces phosphorylation of PYK2 as well as FRA1 in the four M/MSL TNBC cell lines. As seen (Fig 8A), GAS6 slightly enhanced the phosphorylation of PYK2 (pY402) and more strongly of FRA1 (pS265) and AKT (pS473), an established downstream effector of AXL signaling (30). Importantly, pPYK2 and pFRA1 were also observed upon PKC activation by PMA (Fig 5A), consistent with previous reports (29).

Previously, we showed that PYK2 positively regulates STAT3 phosphorylation (11, 52), and further studies showed that STAT3 plays an important role in CSC formation in BC, is implicated in Oct4 and Nanog transcription activation and in BCSCs self-renewal (20, 21). Indeed, inhibition of STAT3 by Stattic reduced the expression of Oct4 protein in the four M/MS cell lines (Fig 5B). STAT3 is also required for conversion of non-stem cancer cells into cancer stem-like cells downstream to IL6 receptor (53). Therefore, we examined the influence of PYK2 or PKCa depletion/inhibition on pSTAT3 under steady-state conditions and in response to IL6 activation. As shown in Fig 8B, IL6 induced strong phosphorylation of STAT3 in three of four M/MS cell lines (SUM159, MDA-MB-231, and BT549), and STAT3 phosphorylation was abolished in PYK2-depleted but not in PKCa-depleted cells, suggesting that PYK2 is essential for IL6-induced phosphorylation of STAT3. Similar effects were obtained under steady-state conditions (Fig S9C), demonstrating the strong impact of PYK2 on pSTAT3. Collectively, we show that PKCa and PYK2 affect AXL level and concomitantly critical signaling pathways and TFs that play central roles in regulating CSC in TNBC including FRA1, SMAD3, STAT3, and TAZ and consequently the transcription of pluripotent TFs Nanog and Oct4 and of stemness phenotype (Fig 8C).

**Discussion**

Targeting of CSCs has been considered as a promising therapeutic approach for human cancer, in particular to recurrent, metastatic, and drug-resistant diseases (18). The major challenges are to identify this minor subpopulation of cancer cells, and eventually the specific molecular targets that eliminate CSCs.

Since the discovery of CSCs in the early 1990s, numerous studies have characterized their unique physiological features of slow proliferation rate, plasticity, self-renewal, and tumor-initiation capacity and concurrently identified discrete cellular markers, many of them are cancer type specific that have been used to isolate CSCs and profiling their transcriptome, proteome, and metabolome (39, 54).

These omics approaches yield stemness-associated transcriptomic signatures, such as the Lim mammory stem cell signature (38) (Fig 5) and uncovered stemness-associated signaling...
Figure 7. TGFβ enhances PYK2 phosphorylation, stemness, and vulnerability to PYK2 and PKC inhibition.

(A) Control, PYK2-, or PKCα-KD SUM159 cells were treated with 2.5 ng/ml TGFβ1 for 72 h in full-growth media and then seeded for mammosphere formation assay. The plot shows the percent of primary mammospheres formed (compared with control). Means ± SD of two independent repeats are shown; *P-value of TGFβ1 treated versus control (t test) < 0.05.

(B) SUM159 cells were stimulated with TGFβ1 (5 ng/ml) for the indicated time periods. Phosphorylation of PYK2(Y402) and SMAD3(S423/425) was examined by Western blot (WB).

(C) Control, PYK2-, or PKCα-KD SUM159 and Hs578T cells were stimulated with TGFβ1 (5 ng/ml) for 30 min. Phosphorylation of PYK2(Y402) and SMAD3(S423/425) was examined by WB.

(D) The indicated mesenchymal/mesenchymal stem-like triple negative breast cancer cell lines were

(A) Control, PYK2-, or PKCα-KD SUM159 cells were treated with 2.5 ng/ml TGFβ1 for 72 h in full-growth media and then seeded for mammosphere formation assay. The plot shows the percent of primary mammospheres formed (compared with control). Means ± SD of two independent repeats are shown; *P-value of TGFβ1 treated versus control (t test) < 0.05.

(B) SUM159 cells were stimulated with TGFβ1 (5 ng/ml) for the indicated time periods. Phosphorylation of PYK2(Y402) and SMAD3(S423/425) was examined by Western blot (WB).

(C) Control, PYK2-, or PKCα-KD SUM159 and Hs578T cells were stimulated with TGFβ1 (5 ng/ml) for 30 min. Phosphorylation of PYK2(Y402) and SMAD3(S423/425) was examined by WB.

(D) The indicated mesenchymal/mesenchymal stem-like triple negative breast cancer cell lines were

(E) % Cell viability

(F) % Cell viability

(G) 1.50 μM PF396 - - + + 1.50 μM PF396 - - + + 2.00 μM RO-31 - + - + 1.00 μM RO-31 - + - + TGFβ1 TGFβ1 SUM159 MDA-MB-231
pathways that are crucial for CSCs survival and self-renewal. Targeting of these CSC-associated pathways has been used as a therapeutic strategy in many preclinical and clinical trials (55). In TNBC, several key pathways have been associated with stemness and proposed to be potent therapeutic targets, including the STAT3/Jak pathway, Wnt/β-Catenin, Notch pathway, Hedgehog, TGFβ, and AXL/GAS6 (3, 6). Importantly, many of these pathways crosstalk with each other, share downstream effectors, and are regulated by common feedback loops, implying that targeting of signaling nodes converging multiple stemness pathways could be an efficient strategy to simultaneously impair several CSC-related pathways and eliminate CSCs with high efficacy.

Here, we identified two signaling nodes, PYK2 and PKCa, that act at the convergent point of several stemness-associated pathways (Figs 5E, 7B and D, and 8), and functionally cooperate to regulate the pluripotent TFs Oct4 and Nanog and consequently stemness in TNBC (Fig 6D).

Previous studies suggested that activation of PKCa by PDGFR is crucial for switching non-CSCs to CSCs in TNBC, and that FRA1 downstream of PKCa regulates the expression of EMT-CSC program (27). Here, we show that PKCa expression is strongly influenced by PYK2 (Fig 1D), that PYK2 is a downstream signaling component of additional key stemness-inducing pathways, including TGFβ and GAS6/AXL (Figs 7 and 8), and that PKCa and PYK2 mutually regulate each other and cooperate to robustly modulate stemness in TNBC (Fig 6). Consistent with their mode of action, our attempt to simultaneously deplete PYK2 and PKCa in M/MSL TNBC cell lines repeatedly failed, and the few cells that survived grew extremely slow (not shown). Nevertheless, we showed that inhibition of their kinase activities using small molecule inhibitors markedly reduced the viability of TGFβ-treated TNBC cells and their co-inhibition had synergistic effects (Fig 7E and F). These results suggest that targeting of PYK2 and PKCa could effectively eliminate CSC-enriched populations. Interestingly, we previously showed that co-targeting of PYK2 and EGFR could be beneficial for basal-like patients with high expression of EGFR (52), and here we propose that co-targeting of PYK2 and PKCa might be more effective for EMT/stemness-associated tumors.

The cooperation between PYK2 and PKCa is also reflected by their complementary influence on AXL levels (Figs 1 and 2); whereas PYK2 depletion/inhibition markedly reduced the protein and transcription levels of AXL, PKCa inhibition mainly affected the protein level of AXL, induced its translocation into an endosomal/lysosomal compartment that was positive for Rab11 and for the MVBs/late endosomal markers CD63/CD9, Lamp1, and lysotracker, and enhanced its lysosomal degradation (Figs 4 and S4). These results imply that PKC inhibition perturbs the endosomal/lysosomal pathway. Although future studies will be required to uncover the underlying mechanism, it is possible that PKC inhibition impairs Rab11-associated functions, as Rab11 was reported to be phosphorylated by PKC (56), and Rab11 depletion induced punctate structures resembling the structures obtained by PKC inhibition (Figs 4A and S4B), and also increased lysotracker staining (35). Importantly, PYK2 was also localized to these structures and colocalized with AXL, demonstrating the mutual interplay between components of the AXL-PYK2-PKCa axis.

The robust effect of PYK2 on AXL was observed in all the M/MSL TNBC and also in other cell types (not shown), further supporting the link between these two kinases (Fig 1D). This was also reflected by dataset analysis of TNBC and the finding that AXL was the top gene among the 16 stemness correlated genes with PYK2 and PKCa stemness signatures (Fig 5D). The substantial effect of PYK2 on AXL is mediated, at least in part, by feedback loop of two transcription regulators, the transcription co-activator TAZ (34) and TF FRA1 (Fig 3). This finding has an important clinical implication as it strongly suggests that inhibition of PYK2 could overcome AXL-associated drug resistance, which is frequently associated with resistance to different anticancer drugs, including chemotherapy (13). Moreover, PYK2 and AXL are highly expressed in immune cells and possibly exhibit a similar mutual influence.

Identification of PYK2 and PKCa as clinically relevant signaling nodes of different stemness-associated pathways (Figs 7 and 8) is reflected by their combined effects on multiple TFs such as STAT3, TAZ, FRA1, and SMAD3 (Figs 2A, 3C, 7C, and 5B) and the subsequent pluripotent TFs Oct4 and Nanog (Fig 6D). Importantly, we have previously showed that PYK2 regulates STAT3 during EMT in TNBC and that STAT3 via a feedback loop regulates PYK2 expression (52, 57). These results highlight how this stemness nexus is convergent and controlled by different feedback loops that together ensure the robustness of stemness phenotype. We, therefore, propose that combined targeting of PYK2 and PKCa could be beneficial for CSCs elimination in TNBC and possibly overcoming drug resistance.

Materials and Methods

Antibodies, reagents, and chemicals

Antibodies to AXL (sc-166268), FRA1 (sc-605), PKCa (sc-208), pPYK2 (Y402, sc-101790), FAK (sc-932), pSTAT3 (sc-8059), STAT3 (sc-483), YAP/TAZ (63.7, sc-101199), Rab11 (sc-9020), and PKC inhibitor RO-31-8220 (sc-200619) were purchased from Santa Cruz Biotechnology. Antibodies to pSMAD3 (9520), SMAD3 (9523), pFAK (8556), pSTAT3 (sc-8059), STAT3 (sc-483), YAP/TAZ (63.7, sc-101199), Rab11 (sc-9020), and PKC inhibitor RO-31-8220 (sc-200619) were purchased from Santa Cruz Biotechnology.

Cell treated with PYK2 (PF396) or PKC (RO-31-8220) inhibitors overnight, and then serum starved for 2 h in presence of inhibitors before exposure to TGFβ1 (5 ng/ml for 30 min). PF396 was applied at 3 μM (+) or 6 μM (+++), whereas RO-31-8220 was applied at 2 μM (++) or 4 μM (+++) for SUM159, and 1 μM (++) or 2 μM (+++) for the other three cell lines. Levels of PYK2, pPYK2 (Y402), SMAD3, and pSMAD3 (S423/S425) were assessed by WB in the indicated cell lines. The indicated cell lines were pre-treated with 10 ng/ml TGFβ1 for 24 h in full growth media. The medium was replaced with fresh media containing the indicated doses of PF396 or RO-31-8220, either alone or in combination. Cell viability was assessed 72 h later by MTT assay. Cell viability was calculated relative to control untreated or TGFβ-treated cells and mean values of % cell viability from two independent experiments are shown for the indicated doses. Complete set of dose response ± SD is presented in Fig S5A. Mean values of % cell viability for the indicated treatment were used to generate dose–response curves for PF396. RO-31-8220 was added at constant concentration of 2 μM for SUM159 and 1 μM for MDA-MB-231. SUM159 or MDA-MB-231 cells were treated with the indicated concentration of PF396 and RO-31-8220 for 72 h with or without TGFβ pre-treatment, and then stained with crystal violet (see the Materials and Methods section). Shown are representative crystal violet staining results of two experiments.

AXL–PYK2–PKCa axis in TNBC stemness Khera et al. https://doi.org/10.26558/lsa.202000985 vol 4 | no 6 | e202000985 12 of 17
AXL-PYK2-PKCα axis in TNBC stemness  

Khera et al.  

Signaling Technologies. Antibodies to CD44 FITC (BY18, 338804) and CD24 APC (ML5, 311118) were purchased from BioLegend. Antibody to α-tubulin (T6074) as well as the following chemicals, Hoechst 33342, Verteporfin (1711461), PF431396 (PZ0185), and Chloroquine (C6628) were purchased from Sigma-Aldrich Israel. Gö6983 (S2911) and GF109203X (S7208) were from Selleck chemicals. Polyclonal anti-PYK2 antibody was prepared as described previously (58). Antibody to CD44 was from Hybridoma clone H4C4. Antibody to Rab4

Figure 8. PYK2 and PKCα function at convergent point of multiple stemness-inducing pathways.  

(A, B) The different mesenchymal/mesenchymal stem-like triple negative breast cancer (TNBC) cell lines were serum starved for 2 h and then stimulated with either GAS6 (A) or IL6 (B). The levels of total and phosphorylated AXL, PYK2, AKT, and FRA1 proteins in response to GAS6 (250 ng/ml) stimulation at the indicated time points was examined by Western blot.  

(B) Phosphorylation of STAT3 (Y702) in response to IL6 (50 ng/ml) stimulation for 30 min in control and PYK2 KD or PKCα KD TNBC mesenchymal/mesenchymal stem-like cells was examined by Western blot.  

(C) A scheme depicting the convergence of stemness promoting pathways at the PYK2 and PKCα signaling nodes. AXL-PYK2-PKCα axis acts at the center of stemness nexus in TNBC that modulates the level and/or activation of multiple transcription factors (TFs). PYK2 and PKCα are the central signaling nodes, converging signaling of different stemness promoting pathways, including TGFβ and IL6 pathways. TGFβ induces PYK2 and PKCα activation (green arrows), whereas PYK2 is required for STAT3 phosphorylation in response to IL6 (red dash arrow). PYK2 and PKCα mutually influence each other, and complementarily modulate the expression/activation of key TFs, including SMAD3, FRA1, TAZ, and STAT3, through phosphorylation, stabilization, and feedback loop mechanisms (blue dash arrows), thereby effectively regulating Nanog and Oct4 pluripotent TFs and stemness phenotype (the three receptors: TGFβR, AXL, and IL6R are illustrated in a schematic simplistic manner without structural details).
were regularly verified to be mycoplasma negative.

Cell culture

All cell lines that were used in the study were originally obtained from ATCC. HCC70, MDA-MB-468, MDA-MB-231, BT549, SUM159, and Hs578T were maintained in RPMI (Gibco BRL). HEK293 cells were maintained in DMEM (Gibco BRL). Media were supplemented with 10% vol/vol fetal bovine serum (Gibco BRL) and 1% vol/vol penicillin–streptomycin mixture (Beit Haemek) unless otherwise stated. Cell lines were washed with cold PBS and lysed in cold lysis buffer (0.5% Triton-X-100, 50 mM Hepes pH 7.5, 100 mM NaCl, 1 mM MgCl2, 50 mM 3′-methylsulphonyl fluoride, 10 μg/ml leupeptin, and 10 μg/ml aprotinin), vortexed, and incubated on ice for 30 min with vortexing at intervals of 10 min. Cleared cell extracts were obtained by centrifuging at 19,300g for 15 min at 4°C. Bradford assay (Bio-Rad) was used to estimate sample protein concentrations and equal amounts of total protein per sample were analyzed on SDS–polyacrylamide gel electrophoresis and Western Transfer using standard procedures. A 5% nonfat dry milk solution in TBS-Tween (0.05%) was used for blocking at room temperature for 1 h. Incubation with secondary antibodies was performed at 4°C overnight on a rocker. Incubation with secondary antibodies was performed at room temperature for 1 h. For densitometric analysis, the intensity of protein bands was measured using the Fiji-ImageJ software (NIH). The band intensities of analyzed proteins of WBs were normalized to that of α-tubulin.

RNA extraction and real-time PCR analysis

RNA was purified using TRI Reagent (T9424; Sigma-Aldrich). cDNA was generated using High-Capacity CDNA Reverse Transcription Kit (Applied Biosystems; Invitrogen). Real-time PCR analysis was performed using SYBR Green as a fluorescent dye, according to the manufacturer’s guidelines using the ABI StepOnePlus 7500 Real-time PCR system (Applied Biosystems; Invitrogen). All experiments were normalized to Actin RNA levels. The primer sequences are provided in Table S3.

Immunofluorescence staining

Cells were treated on sterile coverslips placed in wells of a 24-well plate, washed with PBS at 35°C, and fixed in 4% paraformaldehyde solution, also preheated at 35°C, for 15–20 min at room temperature. The fixed cells were then washed once with room temperature PBS and incubated for 10 min in PBS containing 0.1 M glycerine to quench excess PFA action. This was followed by blocking with TBS containing 0.1% Triton-X-100, 10% goat serum, and 2% BSA for 30 min. Incubation with the primary antibody was carried out at room temperature for 1–2 h, followed by three washes in PBS, and then 1 h incubation with the secondary antibody. The cells were incubated for 5 min with PBS containing 2 μg/ml Hoechst 33342, washed three times with PBS, and mounted on microscopic slides using mounting media (10 mM phosphate buffer, pH 8.0, 16.6% wt/vol Mowiol4–88, and 33% glycerol). The prepared slides were analyzed by using Zeiss LSM800 confocal laser-scanning microscope. Colocalization was calculated using Colocalization Module of ZEN software (Zeiss Microscopy LLC). Pearson’s coefficient and colocalization coefficient for each channel are presented in Table S1.

shRNA lentivirus–mediated knockdown

PYK2 expression was down-regulated by two different shRNAs: shRNA #519 (TRCN00000231519) was purchased from Sigma-Aldrich, whereas the second one (shRNA #5) was prepared as previously described (59). Both shRNA showed similar effects. Experiments shown in the manuscript were performed with shRNA #519. AXL expression was down-regulated by two different shRNAs: shRNA #971 (TRCN0000194971) was kindly provided by Prof. M. Elkabets, whereas shRNA #699 (TRCN0000001038) was kindly provided by Dr. D. Lin. Both shRNA showed similar effects. Experiments shown in the manuscript were performed with shRNA #971. PKCa expression was down-regulated by three different shRNAs: shRNA #690 (TRCN0000001690) was prepared by cloning into pLKO.1-puro lentiviral vector, shRNA #691 (TRCN0000001691), and shRNA #692 (TRCN0000001692) were kindly provided by Prof. RS Harris. The different shRNA showed similar effects. Experiments shown in the manuscript were performed with shRNA #690. FRA1 expression was down-regulated using shRNA sequence TRCN0000019539. The respective shRNA sequences were cloned into the pLKO.1-puro lentiviral vector. Selection medium for infected cells contained added puromycin at 15–2 μg/ml.

Cell viability assay

Cells were plated in 96-well plates and next day treated with TGFβ1 (10 ng/ml) for 24 h. The cells were then treated with the indicated concentrations of PYK2/FAK (PF396), FAK (PF228), or PKC (RO-31-8220) inhibitors, either alone or in combination in fresh media using DMSO as vehicle control. Inhibitor-treatment was continued for 72 h and cell viability was measured by MTT assay (60). Cell viability is shown as percentage of control. Synergy of PYK2 and PKCa inhibitors was calculated by the CompuSyn software using the Chou–Talalay equation. Combination index is given for the concentration of inhibitors that induces a combined effect of 75% cell death.

Dataset analysis

Enrichment of AXL in MSL subtype patients was shown in datasets of TNBC patients taken from Lehmann et al, (28). For subsequent
analysis, gene expression data of TNBC patients were taken from TCGA dataset (n = 142 basal-like BC patients). Cell lines data were taken from the Cancer Cell Line Encyclopedia dataset (n = 54 BC cell lines). GSEA were performed using GSEA software (Broad institute). Single sample gene set enrichment was performed using Gene-Pattern (www.genepattern.org/). All other dataset analysis was performed in R.

**RNAseq**

RNA from PYK2 KD and control MDA-MB-231 cells was extracted by TRizol as described above and used to generate RNAseq libraries applying a bulk adaptation of the MARS-seq protocol, as described previously (61). Libraries were sequenced by the Illumina Novaseq applying a bulk adaptation of the MARS-seq protocol, as described above. RNAseq was performed in two biological replicates.

**Mammosphere assay**

Generation of mammospheres for detection of TICs was performed as described previously (63). In brief, single-cell suspensions were prepared by trypsinization and disengagement using a 25G needle syringe. Cells were seeded at low density (10,000 cells/cm²) in poly-hema–coated six-well plates (poly-hema was dissolved in 95% ethanol, 20 mg/ml). Plates were incubated with the poly-hema over-night in RT. Cells were grown in mammosphere medium (DMEM/F12 medium, without serum, supplemented with 2 mM L-glutamine, and 100 U/ml penicillin/streptomycin, 20 ng/ml EGF, 10 ng/ml FGF and B27 1:50 [Thermo Fisher Scientific]). After 10 d of incubation, the medium was centrifuged (150g for 5 min), the mammospheres were resuspended in 200 μl PBS and placed in a well of a 96-well plate. The entire well was photographed and the diameter of all mammospheres was measured using ZEN lite software (Zeiss). Mammosphere with a diameter above 40 μm were counted. Alternatively, after 10 d in culture, mammospheres were passaged (by trypsinization and a 25-G needle, seeded in the same axis) in TNBC stemness Khera et al., to grow for 7–10 d until colonies were visible under the microscope. Colonies formed were stained with Crystal Violet, photographed, and counted.

**Conflict of Interest Statement**

The authors declare that they have no conflict of interest.
References

1. Donnenberg VS, Donnenberg AD (2005) Multiple drug resistance in cancer revisited: The cancer stem cell hypothesis. J Clin Pharmacol 45: 872–877. doi:10.1177/0022345605276905

2. Tan BT, Park CY, Ailles LE, Weissman IL (2006) The cancer stem cell hypothesis: A work in progress. Lab Invest 86: 1203–1207. doi:10.1038/ lainvest.3700488

3. Angeloni V, Tiberio P, Appietro V, Daidone MG (2015) Implications of stemness-related signaling pathways in breast cancer response to therapy. Somin Cancer Biol 31: 63–51. doi:10.1016/j.semcancer.2014.08.004

4. Park SY, Choi JH, Nam JS (2019) Targeting cancer stem cells in triple-negative breast cancer. Cancers (Basel) 11: 965. doi:10.3390/cancers11070965

5. Collina F, Di Bonito M, Li Bergolis V, De Laurentiis M, Vitagliano C, Cerrone M, Nuzzo F, Cantile M, Botti G (2015) Prognostic value of cancer stem cells markers in triple-negative breast cancer. Biomed Res Int 2015: 158682. doi:10.1155/2015/158682

6. Yousefnia S, Seyed Forootan F, Seyed Forootan S, Nasr Esfahani MH, Gure AO, Haedh K (2020) Mechanistic pathways of malignancy in breast cancer stem cells. Front Oncol 10: 452. doi:10.3389/fonc.2020.00452

7. Lev S (2020) Targeted therapy and drug resistance in triple-negative breast cancer: The EGFR axis. Biochem Soc Trans 48: 657–665. doi:10.1042/bst20191055

8. Shipitsin M, Polyak K (2008) The cancer stem cell hypothesis: In search of definitions, markers, and relevance. Lab Invest 88: 459–463. doi:10.1033/2008.14

9. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704–717. doi:10.1016/j.cell.2008.03.027

10. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J (2008) Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68: 989–997. doi:10.1158/0008-5472.can-07-2017

11. Verma N, Keinan O, Selitrennik M, Karn T, Filipits M, Lev S, Reinhard F, Zhang CC, Shipitsin M, et al (2015) PYK2 sustains endosomal-derived receptor signalling and enhances epithelial-to-mesenchymal transition. Nat Commun 6: 6066. doi:10.1038/ncomms7064

12. Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC, Verma N, Keinan O, Selitrennik M, Karn T, Filipits M, Lev S, Reinhard F, Zhang CC, Shipitsin M, et al (2015) Pyk2 drives self-renewal in triple-negative breast cancer via interaction with Nanog and focal adhesion kinase. Nat Commun 6: 578. doi:10.1038/ncomms10938

13. Dal M, Zhang C, Ali A, Hong X, Tian J, Lo C, Flis-Aime N, Burgos SA, Ali S, Lebrun JJ (2016) CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer. Sci Rep 6: 35388. doi:10.1038/srep35388

14. Wang T, Fahrmann JF, Lee H, Li YJ, Tripathi SC, Yue C, Zhang C, Lifshitz V, Song J, Yuan V, et al (2018) Axl/JAK2-STAT3-regulated fatty acid beta-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance. Cell Metab 27: 136–150.e5. doi:10.1016/j.cmet.2017.11.001

15. Serrano-Oviedo L, Nuncio-Cantarero M, Morcillo-Garcia S, Nieto-jimenez C, Burgos M, Corrales-Sanchez V, Perez-Pena J, Gyorffy B, Ocana A, Galyan-Moya EM (2020) Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer. Cell Oncol (Dordr) 43: 431–444. doi:10.1007/s14452-020-00497-6

16. Tam WL, Lu H, Buikhuisen J, Soh BS, Lim E, Reinhardt F, Wu ZJ, Krall JA, Bierie B, Guo W, et al (2013) Protein kinase C alpha is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell 24: 347–364. doi:10.1016/j.ccell.2013.08.005

17. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: 2750–2767. doi:10.1172/jci45014

18. Lev S, Moreno H, Martinez R, Canoll P, Peles E, Musacchio JM, Plowman GD, Rudy B, Schlessinger J (1995) Protein tyrosine kinase PYK2 involved in Ca2+)-induced regulation of ion channel and MAP kinase functions. Nature 376: 737–745. doi:10.1038/376737a0

19. Sayan AE, Stanford R, Vickery R, Greigerson E, Diesch J, Kubicki K, Edwards R, Pal R, Greaves P, Jain-Ecnonitre I, et al (2012) Farc-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL. Oncogene 31: 1493–1503. doi:10.1038/onc.2011.336

20. Badani M, Prasad M, Balaban N, Zorea J, Yegodayev KM, Joshua BZ, Dinur AB, Grennan R, Rotblat B, Cohen L, et al (2019) Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Kα therapy. JCI Insight 5: e125341. doi:10.1172/jci.insight.125341

21. Leconet W, Chentouf M, du Manoir S, Chevalier C, Sivert A, Ait-Arsa I, Busson M, Jarlier M, Radosvevic-Robin N, Theillet C, et al (2017) Therapeutic activity of anti-AXL antibody against triple-negative breast cancer patient-derived xenografts and metastasis. Clin Cancer Res 23: 2806–2816. doi:10.1158/1078-0432.ccr-16-1316

22. Hoi JP, Mayro B, Pendergest AM (2019) A TAZ-AXL-ABL2 feed-forward signaling axis promotes lung adenosarcoma brain metastasis. Cell Rep 29: 3421–3434.e8. doi:10.1016/j.celrep.2019.11.018
Khera et al. (2020) Synthetic lethal combination targeting BET activators with BET inhibitors synergizes with JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell Signal 25: 961–969. doi:10.1016/j.cellsig.2013.01.007